

✓Gi Med Onc @bccancer, Clin Asst Prof @UBCDoM. Music, Literature, Pet, and Travel ! Tweets are my own. Ret. ≠ Endors.


Genome-directed treatment targets and mutational signature biomarkers: a retrospective, pan-solid tumour analysis #cancer #oncology #MedX @OncoAlert thelancet.com/journals/lanon…

🚨 dMMR ≠ Lynch syndrome! A crucial distinction every oncologist should know. A new Lancet review highlights the diagnostic pathway: 🔬 MLH1/PMS2 loss? Check BRAF V600E and/or MLH1 methylation. 🧬 MSH2/MSH6 or isolated MSH6/PMS2 loss? Consider germline testing. 🔍 Germline negative? Look for double-somatic MMR alterations. 💡 Key message: Tumour MMR deficiency is a starting point, not a hereditary cancer diagnosis. 📊 Save this diagnostic algorithm! @oncoalert @esmo_open @myesmo @asco #LynchSyndrome #PrecisionOncology Full paper link in comment below ⬇️.

🆕 Article in press: Circulating tumor DNA to direct adjuvant immunotherapy across mismatch repair-deficient solid tumors @YJanjigianMD 🔗 doi.org/10.1016/j.annonc.202…

Before a liver transplant, immunotherapy can shrink liver cancer enough to qualify — but it can also trigger rejection. In 408 patients, waiting more than 90 days after the last dose halved rejection risk. @UHN's Arndt Vogel is among the authors: doi.org/10.1016/j.cgh.2026.0…

Are you like me, feeling intimidated by and unsure about the management of patient with mixed neuroendocrine/non-neuroendocrine neoplasms (MiNENs) of gastroenteropancreatic origin? If so, this is a review article you will want to read. Excellent @ENETS_ORG position statement, led by @FRANCES88189587 and a panel of folks who know their stuff. Check it out! onlinelibrary.wiley.com/doi/…

Were you looking for an excellent review on neuroendocrine neoplasm pathology focusing on the challenges of biopsy diagnoses written by true experts in the field? Worry not, I got you... link.springer.com/article/10…

Look at these curves - 🔥 NICHE-2 at five years - Phase 2 (The Lancet) 🎯 Stage II–III dMMR colon cancer, before surgery 💊 Ipilimumab ×1 + nivolumab ×2, then resection 👥 111 per-protocol patients, six Dutch hospitals ✅ 3-year DFS 100% at a median 58.7 mo ✅ 5-year OS 100% (exploratory) 🩸 ctDNA cleared in 80/97 before surgery, all negative after ⚠️ Single-arm, no comparator The pathological response rates from NICHE-2 were already striking; this is the survival follow-up that tells us they held. Zero recurrences across 111 patients, after only roughly a month of treatment w/o chemo before surgery. The comparison that now matters is with *ATOMIC*, which added atezolizumab to adjuvant FOLFOX after surgery: two routes to curing dMMR colon cancer, one of them with six months of chemotherapy and one without. NICHE-2 is single-arm, so one can say that a randomized comparison is still owed before it replaces surgery-first. #CRC #dMMR thelancet.com/journals/lance…

Why does immunotherapy work in MSI-H but rarely in MSS colorectal cancer? A new Science paper offers an interesting clue: in patient tumors, MSI-H cancers have more Th1-like CD4+ T cells that help drive antitumor immunity, while MSS tumors have more suppressive Tregs. In MSS mouse models, adding an OX40 agonist to anti-PD-1 improved tumor control and survival. Still preclinical, but could targeting CD4+ T cells help overcome immunotherapy resistance in MSS colorectal cancer? @ScienceMagazine

🧪 # — SIERRA, Phase IIIb | Journal of Hepatology Patients with poor prognostic features - Child-Pugh B liver function, ECOG 2, or main-trunk portal vein thrombosis (Vp4) - are routinely excluded from phase III HCC trials. 🎯 This study gave STRIDE (tremelimumab + durvalumab) to 👥 111 patients: Child-Pugh B7/B8 44 · ECOG 2 47 · Vp4 PVTT 20 ⚠️ Grade 3/4 related AEs at 6 mo: 19.8% overall, 25.0% in Vp4 📊 ORR 14.4% overall · ECOG 2 21.3% · Vp4 15.0% 📉 Child-Pugh B ORR only 6.8% This is the patient in clinic every week who was never in HIMALAYA. Toxicity looks manageable across all three cohorts, but the Child-Pugh B response rate of 6.8% is the sobering line - liver reserve still limits what immunotherapy can do. #GIOnc #HCC #LiverCancer pubmed.ncbi.nlm.nih.gov/4283…

Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR CRC: pls 2 UNICORN trial @NatureMedicine 👉pMR rate: 0% in pMMR BOT 36% in pMMR BOT + BAL 36% in dMMR BOT 100% in dMMR BOT + BAL 🧐interesting efficacy for BOT + BAL in early pMMR or dMMR CC @myESMO @ASCO

Once you decide on your occupation, you must immerse yourself in your work. You have to fall in love with your work. Never complain about your job. You must dedicate your life to mastering your skill. From "Jiro Dreams of Sushi"

🌍 NCCN Colon Cancer v3.2026 (JNCCN Guidelines Insights) The clinical changes now in force came in Versions 1.2026 and 2.2026. The biggest are: 💊 Aspirin for tumors with somatic PI3K pathway alterations ✅ Atezolizumab + FOLFOX/CAPEOX: preferred adjuvant option in stage III dMMR (ATOMIC, DFS HR 0.50) - although I still think we don't need folfox here. ✅Neoadjuvant immunotherapy for dMMR T4 or bulky tumors ✅Thermal ablation for small liver metastases ✅ Encorafenib + anti-EGFR + FOLFOX or FOLFIRI: preferred 1L in BRAF V600E mCRC (BREAKWATER, OS HR 0.49) 🧬 Pretreatment DPYD testing, after the FDA label change for capecitabine and 5-FU #CRC #ColonCancer #NCCN #DPYD #GIOnc jnccn.org/view/journals/jncc…

🔥 New data from the global phII AZUR-1 trial published at #ESMO26 Dostarlimab monotherapy in untreated stage II/III dMMR/MSI-H LARC (154 pts, 42 centers) 👉 >90% of pts with no evidence of disease progression to date 👉 98% of cCR maintained ≥12 months, no recurrences

5/6 Cancer vaccines could eventually move into prevention or interception: "In theory, a vaccine against 25 recurrent mutational hotspots in genes such as KRAS, BRAF, and PIK3CA could target mutations found in more than 70% of colorectal, pancreatic, uterine, and melanoma..."

🧬 Liver-limited mCRC | 9 trials (n=855) 🔪 357 underwent liver resection 📈 Post-op DFS strongly correlated with OS (ρ=0.73) ⏳ Early relapse (<6 mo) may not rule out surgical benefit in high-tumour-burden patients (exploratory signal). 🔗 doi.org/10.1016/j.esmoop.202… @OncoAlert